Literature DB >> 21284704

Kava, the anxiolytic herb: back to basics to prevent liver injury?

Rolf Teschke1, Jerome Sarris, Xaver Glass, Johannes Schulze.   

Abstract

The use of the anxiolytic herb kava has caused toxic liver injury in Western countries and economic problems in South Pacific Islands due to tthe regulatory ban on kava. This analysis shows poor quality of kava raw material as a cause for its toxicity and suggests preventative measures by going back to the traditional use of kava for the sake of the patients and the South Pacific economy.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21284704      PMCID: PMC3045554          DOI: 10.1111/j.1365-2125.2010.03775.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  The safety of kava: a regulatory perspective.

Authors:  W N Richardson; L Henderson
Journal:  Br J Clin Pharmacol       Date:  2007-07-04       Impact factor: 4.335

2.  Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways.

Authors:  Ping Zhou; Shimon Gross; Ji-Hua Liu; Bo-Yang Yu; Ling-Ling Feng; Jan Nolta; Vijay Sharma; David Piwnica-Worms; Samuel X Qiu
Journal:  FASEB J       Date:  2010-08-09       Impact factor: 5.191

Review 3.  Kava--the unfolding story: report on a work-in-progress.

Authors:  Alison Denham; Michael McIntyre; Julie Whitehouse
Journal:  J Altern Complement Med       Date:  2002-06       Impact factor: 2.579

Review 4.  Kava extracts: safety and risks including rare hepatotoxicity.

Authors:  R Teschke; W Gaus; D Loew
Journal:  Phytomedicine       Date:  2003       Impact factor: 5.340

5.  Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases.

Authors:  Rolf Teschke; Alexander Schwarzenboeck; Karl-Heinz Hennermann
Journal:  Eur J Gastroenterol Hepatol       Date:  2008-12       Impact factor: 2.566

Review 6.  Kava: an overview.

Authors:  Y N Singh
Journal:  J Ethnopharmacol       Date:  1992-08       Impact factor: 4.360

Review 7.  Kava hepatotoxicity: a European view.

Authors:  Rolf Teschke; Alexander Schwarzenboeck; Ahmet Akinci
Journal:  N Z Med J       Date:  2008-10-03

8.  Quantification of kavalactones and determination of kava (Piper methysticum) chemotypes using near-infrared reflectance spectroscopy for quality control in vanuatu.

Authors:  Privat Lasme; Fabrice Davrieux; Didier Montet; Vincent Lebot
Journal:  J Agric Food Chem       Date:  2008-06-10       Impact factor: 5.279

9.  A re-evaluation of kava (Piper methysticum).

Authors:  E Ernst
Journal:  Br J Clin Pharmacol       Date:  2007-06-06       Impact factor: 4.335

Review 10.  Toxicity of kava pyrones, drug safety and precautions--a case study.

Authors:  Johannes Schulze; Walter Raasch; Claus-Peter Siegers
Journal:  Phytomedicine       Date:  2003       Impact factor: 5.340

View more
  7 in total

Review 1.  Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.

Authors:  Jerome Sarris; Erica McIntyre; David A Camfield
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

2.  Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited.

Authors:  Rolf Teschke; Jerome Sarris; Isaac Schweitzer
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

Review 3.  Herbal hepatotoxicity: a critical review.

Authors:  Rolf Teschke; Christian Frenzel; Xaver Glass; Johannes Schulze; Axel Eickhoff
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

Review 4.  The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges.

Authors:  Rolf Teschke; Axel Eickhoff
Journal:  Int J Mol Sci       Date:  2016-03-31       Impact factor: 5.923

5.  Measuring the chemical and cytotoxic variability of commercially available kava (Piper methysticum G. Forster).

Authors:  Amanda C Martin; Ed Johnston; Chengguo Xing; Adrian D Hegeman
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

6.  Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism.

Authors:  Han Chow Chua; Emilie T H Christensen; Kirsten Hoestgaard-Jensen; Leonny Y Hartiadi; Iqbal Ramzan; Anders A Jensen; Nathan L Absalom; Mary Chebib
Journal:  PLoS One       Date:  2016-06-22       Impact factor: 3.240

Review 7.  Kava as a Clinical Nutrient: Promises and Challenges.

Authors:  Tengfei Bian; Pedro Corral; Yuzhi Wang; Jordy Botello; Rick Kingston; Tyler Daniels; Ramzi G Salloum; Edward Johnston; Zhiguang Huo; Junxuan Lu; Andrew C Liu; Chengguo Xing
Journal:  Nutrients       Date:  2020-10-05       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.